Cg Oncology Common Stock Market Value
| CGON Stock | 40.37 0.33 0.82% |
| Symbol | CGON |
CG Oncology Common Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CG Oncology. If investors know CGON will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CG Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.05) | Revenue Per Share | Quarterly Revenue Growth 37.744 | Return On Assets | Return On Equity |
The market value of CG Oncology Common is measured differently than its book value, which is the value of CGON that is recorded on the company's balance sheet. Investors also form their own opinion of CG Oncology's value that differs from its market value or its book value, called intrinsic value, which is CG Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CG Oncology's market value can be influenced by many factors that don't directly affect CG Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CG Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if CG Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CG Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
CG Oncology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to CG Oncology's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of CG Oncology.
| 12/07/2025 |
| 01/06/2026 |
If you would invest 0.00 in CG Oncology on December 7, 2025 and sell it all today you would earn a total of 0.00 from holding CG Oncology Common or generate 0.0% return on investment in CG Oncology over 30 days. CG Oncology is related to or competes with Celcuity LLC, Ascentage Pharma, Centessa Pharmaceuticals, Apogee Therapeutics, Xenon Pharmaceuticals, Travere Therapeutics, and Ultragenyx. CG Oncology is entity of United States. It is traded as Stock on NASDAQ exchange. More
CG Oncology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure CG Oncology's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess CG Oncology Common upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.84 | |||
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 15.97 | |||
| Value At Risk | (4.35) | |||
| Potential Upside | 5.14 |
CG Oncology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for CG Oncology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as CG Oncology's standard deviation. In reality, there are many statistical measures that can use CG Oncology historical prices to predict the future CG Oncology's volatility.| Risk Adjusted Performance | 0.0236 | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | (0.32) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0729 |
CG Oncology Common Backtested Returns
As of now, CGON Stock is very steady. CG Oncology Common retains Efficiency (Sharpe Ratio) of close to zero, which signifies that the company had a close to zero % return per unit of price deviation over the last 3 months. We have found twenty-eight technical indicators for CG Oncology, which you can use to evaluate the volatility of the firm. Please confirm CG Oncology's Standard Deviation of 3.21, market risk adjusted performance of 0.0829, and Coefficient Of Variation of 4601.9 to double-check if the risk estimate we provide is consistent with the expected return of 0.0231%. The firm owns a Beta (Systematic Risk) of 0.82, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, CG Oncology's returns are expected to increase less than the market. However, during the bear market, the loss of holding CG Oncology is expected to be smaller as well. CG Oncology Common today owns a risk of 3.14%. Please confirm CG Oncology Common coefficient of variation, semi variance, period momentum indicator, as well as the relationship between the treynor ratio and daily balance of power , to decide if CG Oncology Common will be following its current price history.
Auto-correlation | -0.72 |
Almost perfect reverse predictability
CG Oncology Common has almost perfect reverse predictability. Overlapping area represents the amount of predictability between CG Oncology time series from 7th of December 2025 to 22nd of December 2025 and 22nd of December 2025 to 6th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of CG Oncology Common price movement. The serial correlation of -0.72 indicates that around 72.0% of current CG Oncology price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.72 | |
| Spearman Rank Test | -0.49 | |
| Residual Average | 0.0 | |
| Price Variance | 0.43 |
CG Oncology Common lagged returns against current returns
Autocorrelation, which is CG Oncology stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting CG Oncology's stock expected returns. We can calculate the autocorrelation of CG Oncology returns to help us make a trade decision. For example, suppose you find that CG Oncology has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
CG Oncology regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If CG Oncology stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if CG Oncology stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in CG Oncology stock over time.
Current vs Lagged Prices |
| Timeline |
CG Oncology Lagged Returns
When evaluating CG Oncology's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of CG Oncology stock have on its future price. CG Oncology autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, CG Oncology autocorrelation shows the relationship between CG Oncology stock current value and its past values and can show if there is a momentum factor associated with investing in CG Oncology Common.
Regressed Prices |
| Timeline |
Pair Trading with CG Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CG Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CG Oncology will appreciate offsetting losses from the drop in the long position's value.Moving against CGON Stock
The ability to find closely correlated positions to CG Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CG Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CG Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CG Oncology Common to buy it.
The correlation of CG Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CG Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CG Oncology Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CG Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out CG Oncology Correlation, CG Oncology Volatility and CG Oncology Alpha and Beta module to complement your research on CG Oncology. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
CG Oncology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.